LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
暂无分享,去创建一个
R M Schultz | S. B. Gates | R. Schultz | C. Shih | G. P. Beardsley | E. A. Rayl | L. L. Habeck | G P Beardsley | L G Mendelsohn | V. Patel | B. Moroson | J R Bewley | S. L. Andis | M. Ratnam | B A Moroson | C Shih | V J Chen | L S Gossett | S B Gates | W C MacKellar | L L Habeck | K A Shackelford | D J Soose | V F Patel | S L Andis | E A Rayl | W Kohler | M Ratnam | V. Chen | J. Bewley | L. Mendelsohn | K. Shackelford | L. S. Gossett | W. Mackellar | D. Soose | W. Kohler | Katherine A. Shackelford | C. MackellarWarren | G. Beardsley | L. G. Mendelsohn
[1] I. Goldman,et al. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. , 1984, Cancer research.
[2] G. P. Beardsley,et al. The Human purH Gene Product, 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase/IMP Cyclohydrolase , 1996, The Journal of Biological Chemistry.
[3] D. W. Fry,et al. Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. , 1982, The Journal of biological chemistry.
[4] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[5] R. Moran,et al. Mouse cDNAs encoding a trifunctional protein of de novo purine synthesis and a related single-domain glycinamide ribonucleotide synthetase. , 1993, Gene.
[6] D. Jodrell,et al. ICI D1694, an inhibitor of thymidylate synthase for clinical study. , 1991, Advances in experimental medicine and biology.
[7] A. Hayter,et al. Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. , 1991, Journal of medicinal chemistry.
[8] R. Schilsky,et al. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. , 1982, The Journal of clinical investigation.
[9] R. Pazdur,et al. Thymidylate synthase inhibitors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] B. Shane. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. , 1989, Vitamins and hormones.
[11] L. Kèlland,et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. , 1995, British Journal of Cancer.
[12] P F Morrison,et al. Folate cycle kinetics in human breast cancer cells. , 1989, The Journal of biological chemistry.
[13] D. Priest,et al. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. , 1995, Cancer research.
[14] G. Henderson,et al. Transport of folate compounds by leukemic cells. Evidence for a single influx carrier for methotrexate, 5-methyltetrahydrofolate, and folate in CCRF-CEM human lymphoblasts. , 1987, Biochemical pharmacology.
[15] F. Sirotnak. Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer. , 1985, Cancer research.
[16] I. Judson,et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.
[17] J. Morrison,et al. Human dihydrofolate reductase: reduction of alternative substrates, pH effects, and inhibition by deazafolates. , 1992, Biochemistry.
[18] H. Burris,et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Mackenzie,et al. Methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. A multifunctional protein from porcine liver. , 1977, The Journal of biological chemistry.
[20] J. Galivan. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. , 1980, Molecular pharmacology.
[21] J. Barredo,et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. , 1992, Journal of medicinal chemistry.
[22] D. Rodbard,et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. , 1985, The Journal of biological chemistry.
[23] R. Jackson,et al. Kinetic simulation of anticancer drug interactions. , 1980, International journal of bio-medical computing.
[24] A. Tse,et al. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. , 1991, Biochemistry.
[25] Y. Cheng,et al. Activity of the new antifolate N10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase, and KB cells containing different levels of dihydrofolate reductase. , 1985, Cancer research.
[26] F. Maley,et al. Catalytically active cross-species heterodimers of thymidylate synthase. , 1993, Biochemistry.
[27] C. Allegra,et al. The kinetics of methotrexate polyglutamation in human breast cancer cells. , 1987, Archives of biochemistry and biophysics.
[28] R. Schultz,et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. , 1995, Molecular pharmacology.
[29] J F Morrison,et al. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.
[30] R. Matthews,et al. Studies on the polyglutamate specificity of methylenetetrahydrofolate dehydrogenase from pig liver. , 1984, Biochemistry.
[31] P. Elwood,et al. Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells. , 1992, The Journal of biological chemistry.
[32] C. Shih,et al. The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. , 1989, The Journal of biological chemistry.
[33] D. Newell,et al. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. , 1988, Biochemical pharmacology.
[34] R. Rozen,et al. Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. , 1988, The Journal of biological chemistry.
[35] R. Moran,et al. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. , 1989, The Journal of biological chemistry.
[36] R. Moran,et al. Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin. , 1985, Journal of medicinal chemistry.
[37] M. Kris,et al. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. , 1988, Cancer research.
[38] B. Chabner,et al. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. , 1983, The Journal of clinical investigation.
[39] D. Newell,et al. Quinazoline antifolates inhibiting thymidylate synthase: synthesis of four oligo(L-gamma-glutamyl) conjugates of N10-propargyl-5,8-dideazafolic acid and their enzyme inhibition. , 1989, Journal of medicinal chemistry.
[40] N. Muthukumaraswamy,et al. 10-Formyltetrahydrofolate synthetase. Evidence for a conformational change in the enzyme upon binding of tetrahydropteroylpolyglutamates. , 1987, The Journal of biological chemistry.
[41] A. Antony,et al. The biological chemistry of folate receptors. , 1992, Blood.
[42] D. T. Blankenship,et al. Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells. , 1983, Biochemistry.
[43] G. Curt,et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.
[44] C. Allegra,et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[45] Raymond L. Blakley,et al. Kinetics of the formation and isomerization of methotrexate complexes of recombinant human dihydrofolate reductase. , 1988, The Journal of biological chemistry.
[46] G. Peters,et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. , 1995, Molecular pharmacology.
[47] W. Sirawaraporn,et al. Expression of human thymidylate synthase in Escherichia coli. , 1989, The Journal of biological chemistry.